跳至主要内容
临床试验/NCT05185544
NCT05185544尚未招募不适用

Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Shanghai Zhongshan Hospital0 个研究点目标入组 50 人开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
主要终点
Tumor Regression Grade

研究概览

简要总结

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged between 18 and 75 years;
  • Lung adenocarcinoma;
  • The patient is able to receive neoadjuvant pemetrexed and cisplatin chemotherapy
  • 4 .The patient is able to understand and comply with the study and has provided written informed consent.

排除标准

  • Patients with a history of lung surgery;
  • Postoperative pathology showed non-primary lung cancer;
  • Patients with a history of other tumors;
  • Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
  • Unable to cooperate with the researchers because of dementia or cognitive decline
  • Other situations that are not in conformity with the standards and requirements of this trial.

结局指标

主要结局

Tumor Regression Grade

时间窗: 1-2 Weeks after enrollment (after Surgery)

次要结局

未报告次要终点

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Sponsor

相似试验